Comparative Pharmacology
Head-to-head clinical analysis: HYDREA versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDREA versus XTANDI.
HYDREA vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyurea inhibits ribonucleotide reductase, thereby reducing the conversion of ribonucleotides to deoxyribonucleotides, which impairs DNA synthesis and leads to cell cycle arrest in S phase. It also induces fetal hemoglobin (HbF) production by increasing nitric oxide and soluble guanylyl cyclase activity.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
20-30 mg/kg orally once daily; typical adult dose 500 mg to 1.5 g daily. Maximum dose 2 g per day.
160 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 3-4 hours in patients with normal renal function. In patients with creatinine clearance <60 mL/min, half-life may be prolonged up to 8-12 hours, necessitating dose adjustment.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Renal excretion is the primary route of elimination, with 50-80% of an administered dose recovered as unchanged drug in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic